Spesolimab for Treatment of GPP
Experts discuss spesolimab, an IL-36 inhibitor, that was recently FDA approved for treatment of GPP.
EP: 1.Prevalence of Rare Dermatological Disorders
EP: 2.Symptoms of Rare Dermatological Disorders
EP: 3.Pathophysiology of GPP, PPP, and SJS
EP: 4.GPP, PPP and SJS: Typical Patient Journey
EP: 5.Diagnosis of Rare Dermatological Disorders
EP: 6.Differential Diagnosis of Rare Skin Conditions
EP: 7.Challenges in Managing Rare Skin Conditions
EP: 8.Initial Management Of Patients With Rare Dermatological Disorders
EP: 9.Use of Biologics in Rare Dermatologic Disorders
Now Viewing
EP: 10.Spesolimab for Treatment of GPP
EP: 11.Future Treatment Outlook for Rare Dermatological Disorders
EP: 12.Improving Recognition and Referral of Rare Conditions in Rare Setting
EP: 13.Patient Subgroups and Educational Opportunities in Rare Dermatological Disorders
EP: 14.Recommendations for Management of Rare Dermatological Disorders in Critical Care Setting
Recent Videos
Related Content
